Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/4/18 → 11/4/22 |
Funding
- Pharmaceutical Research Associates Incorporated: $105,483.00
A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Compared to its Individual Components in Subjects With Early Park
- Guttuso, Thomas (PI)
Project: Research